{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:58:35Z","timestamp":1791503915082,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.clindermatol.2020.12.012","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T21:04:53Z","timestamp":1608152693000},"page":"52-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?"],"prefix":"10.1016","volume":"39","author":[{"given":"Aikaterini","family":"Patsatsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.12.012_bib0001","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0002","doi-asserted-by":"crossref","first-page":"e13475","DOI":"10.1111\/dth.13475","article-title":"Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration","volume":"33","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jaad.2020.04.085","article-title":"Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment","volume":"83","author":"Gisondi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.19158","article-title":"The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.clindermatol.2020.12.012_bib0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/09546634.2020.1757605","article-title":"Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears","volume":"31","author":"Megna","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0007","first-page":"e13680","article-title":"Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak","volume":"33","author":"Giulia","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0008","doi-asserted-by":"crossref","first-page":"e13765","DOI":"10.1111\/dth.13765","article-title":"Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID -19 pandemic: a single-center real-life experience","volume":"33","author":"Rossi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16527","article-title":"Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports","volume":"34","author":"Ferrucci","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0010","article-title":"No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area-Bergamo, Lombardy, Italy","volume":"34","author":"Carugno","year":"2020","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0011","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/1203475420930223","article-title":"Patient-driven discontinuation of dupilumab during the COVID-19 pandemic in two academic hospital clinics at the University of Toronto","volume":"24","author":"Georgakopoulos","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0012","doi-asserted-by":"crossref","first-page":"e13491","DOI":"10.1111\/dth.13491","article-title":"Comment on \u201cAntipsoriatic treatments during COVID-19 outbreak","volume":"33","author":"Abdelmaksoud","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0013","doi-asserted-by":"crossref","first-page":"13345","DOI":"10.1111\/dth.13345","article-title":"Antipsoriatic treatments during COVID-19 outbreak","volume":"33","author":"Di Lernia","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0014","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jaad.2020.03.103","article-title":"Reply to: \u201cCOVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.clindermatol.2020.12.012_bib0015","article-title":"Biologics for psoriasis during COVID-19 outbreak","volume":"82","author":"Reply","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0016","first-page":"6","article-title":"Biologic therapy for psoriasis during the covid-19 outbreak is not a choice","volume":"6634","author":"Bardazzi","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0017","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jdv.16515","article-title":"Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice","volume":"34","author":"Gisondi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16571","article-title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor","volume":"34","author":"Balestri","year":"2020","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16468","article-title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor","volume":"34","author":"Messina","year":"2020","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0020","doi-asserted-by":"crossref","first-page":"e13434","DOI":"10.1111\/dth.13434","article-title":"COVID-19 and psoriasis\u00a0: should we fear for patients treated with biologics?","volume":"33","author":"Amerio","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0021","first-page":"1","article-title":"Immunomodulators and immunosuppressants in the era of SARS-CoV-2-could laboratory tests be the missing link?","volume":"6634","author":"Alpalh\u00e3o","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dth.13415","article-title":"Psoriasis and psoriatic arthritis: how to manage immunosuppressants in COVID-19 days","volume":"33","author":"Coletto","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0023","first-page":"e13467","article-title":"Biologics for psoriasis in COVID-19 era: what do we know?","author":"Megna","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0024","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.jaad.2020.04.030","article-title":"Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: safety considerations","volume":"83","author":"Blaszczak","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0025","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jaad.2020.04.098","article-title":"Potential role of Janus kinase inhibitors in COVID-19","volume":"145","author":"Napolitano","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.012_bib0026","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.19161","article-title":"Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20302479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20302479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:18:11Z","timestamp":1760033891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20302479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0738081X20302479"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.012","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}